Dr. Czerkinsky is currently Research Director at the Institute of Molecular and Cellular Pharmacology, a research organization spearheaded by the French National Research Council (CNRS), the National Institute of Health and Medical Research (INSERM) and the University of Nice at Sophia Antipolis (France). He previously served as Deputy Director General and Head of R&D at the International Vaccine Institute (Seoul, South Korea) and as Professor at Seoul National University, Korea University, and Göteborg University (Sweden). He has authored more than 180 scientific publications and is an inventor of more than 20 patents in the field of immunology and vaccine science.
He is now a professor of Gunma University Graduate School of Health Sciences in Japan. He got the professorship in 1993 and his main research theme is NKT cells. Before coming back to Japan, he has worked at Max Planck Institute for Infection Biology in Berlin, Germany as a higher ranking senior scientist approx. 10 years with Prof. Dr. Stefan H. E. Kaufman, who was a president of International Union of Immunological societies, and published many articles in prestigious journals with high impact factor. Although he is an associate editor in this journal, he also serves as editors in more than 40 journals including Editor-in-Chief. He has concentrated on identification of new natural ligand(s) for invariant NKT cells and nowadays he has succeeded to determine their chemical structures. Thus, he is a leading scientist in the field of NKT cells.
Dr. Umehara is Director of North County Center for RA and Autoimmune Diseases (NCC-RA2ID), Hayashi Hospital. He is a Rheumatologist with wide knowledge of Clinical and Basic Immunology. Previously, Dr. Umehara was professor and chairman, Kanazawa Medical University, and served as the Japanese director of Sjögren’s International Collaborative Clinical Alliance (SICCA) during 2006 to 2014. He was also a chairman of All Japan IgG4-RD team by Health, Labor and Welfare, Japan (2011-2013) and published comprehensive diagnostic criteria for IgG4-RD, 2011.
Currently, I am working as an Associate Professor at the University of Hail, KSA. My research interests encompass immunology, biochemistry and cell biology. After obtaining my PhD in Medical Biochemistry from AMU, Aligarh, India, I worked as a Postdoctoral Research Associate for many years at the Institute of Infection and Immunity, Cardiff University, UK. I have worked on the development of human γδ-T cell based cancer immunotherapy and cancer immunology. I have more than 16 years of research experience and published a number of peer-reviewed research and review articles in international journals.
Prof Moganavelli (Mogie) Singh obtained a PhD (Biochemistry) from the University of KwaZulu-Natal in 2006. She is currently an Associate Professor, Researcher and Head of the Nano-Gene and Drug Delivery Laboratory at the University of KwaZulu-Natal, Durban, South Africa. Her interdisciplinary research includes the development and biological evaluation of inorganic nanoparticles as potential gene and drug delivery vehicles for cancer and in immunotherapy. Nanoparticles currently under evaluation in her laboratory are lipid, gold, silver, platinum, selenium, copper, and bimetallic nanoparticles. She is also involved in anti-cancer studies of chemical and medicinal plant compounds. Prof Singh is a member of the European and American Gene and Cell Therapy Societies with over 90 publications to her credit.
After getting my MSc. title in biochemistry at the Jagiellonian University (Cracow, Poland) in 2000, I completed my PhD in 2004 at the IPK Gatersleben (Germany) for my work on embryonic stem cells. Next, I moved to Switzerland and worked at the University Hospital Basel and University of Zurich as a post-doctoral fellow in the field of heart-specific autoimmunity and myocarditis. In 2015, I established my research group at the Jagiellonian University Medical College and continue my work on myocarditis.
Am presently the Chair, Department of Pediatrics and heading the Pediatric Allergy and Immunology Unit at the Advanced Pediatrics Center in PGI, Chandigarh, India. Am also the Principal Investigator for Centre for Advanced Research in Primary Immunodeficiency Diseases, Indian Council of Medical Research, PGI Chandigarh. Awarded James Flett Endowment Prize and Gold Medal (1985) by Indian Academy of Pediatrics; Zydus Oration (2003) and IRA Oration (2010) by Indian Rheumatology Association; Von Pirquet Oration (2003) and V. Raju Gold Medal (2004) by Indian College of Allergy and Applied Immunology; Chaturvedi Kalawati Jagmohan Das Memorial Awards (2009 and 2011) by Indian Council of Medical Research.
Gregory B. Lesinski, PhD, MPH, is Associate Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, Georgia. Dr. Lesinski's research is focused on gaining a greater understanding of the interactions between the host immune system and tumor cells. The ultimate goal is to use this knowledge to develop novel therapeutic or chemo-preventative approaches to help patients with cancer, and improve upon existing therapies. Of particular interest are modulation of cytokines and downstream signaling pathways to maximize the effect of immune based therapy.
Dr. Bright is a Professor of Immunology in the School of Medicine at Texas Tech University Health Sciences Center. He earned a PhD from the University of Texas Health Sciences Center in 1994, and was awarded an Intramural Research Training Award Fellowship to study tumor immunology in the Surgery Branch of the National Cancer Institute, NIH. He has more than 20 years of experience in research focusing on tumor immunity, has been funded by the NIH, the American Cancer Society and the DOD CDMRP, and has over 90 publications in the area of tumor immunology and tumor vaccines.
Dr Taylor-Robinson received a BSc in medical microbiology (immunology major) from University College London and a PhD in parasite immunology from the University of Glasgow for work on cellular immunity to malaria. He has 30 years’ research experience of infectious disease immunology, with a focus on malaria, dengue and other mosquito-borne diseases, now covering Zika. He is currently Professor of Immunology & Haematology at Central Queensland University where he investigates pathogens affecting human wellbeing in rural Australia. He has authored over 150 peer-reviewed journal.
Dr. Subbarao Bondada is a Professor in the Department of Microbiology, Immunology and Molecular Genetics at the University of Kentucky Chandler Medical Center. He obtained his Ph. D. from the Tata Institute of Fundamental Research, Mumbai, India. He has authored more than 130 scientific publications. His research is focused on activation of normal B lymphocytes and growth regulation of malignant B cells. He is currently an Associate Editor for Frontiers in Immunology and PLOS One.
John Chan received his MD degree from Albert Einstein College of Medicine. He then did a fellowship in Infectious Diseases at Montefiore Medical Center/Albert Einstein College of Medicine. He is currently professor of Medicine and Microbiology & Immunology at Albert Einstein College of Medicine. His research focuses on the interaction between Mycobacterium tuberculosis, the causative agent of tuberculosis, and its host, with the goals of understanding the lung immune response to the tubercle bacillus, deciphering the mechanisms by which this pathogen evades host defense to enter a latent state and subsequently reactivates, and developing novel effective anti-tuberculosis interventions including vaccines.
Dr. Gunnur Deniz is a Professor of Department of Immunology, Institute of Experimental Medicine (DETAE), Istanbul University, Istanbul. She is graduated from Istanbul University, Faculty of Sciences, Department of Biology in 1985 and received her M.Sc. degree in Physiology in 1989. Between 1990-1994 she was granted by the Turkish Republic Higher Education Council (YÖK) with a PhD fellowship to study at the Department of Immunology, University of Liverpool and received her PhD degree in immunology in 1994. She is the chairman of the Immunology Department at DETAE since 2002, and has also been working as a Vice President of DETAE since 2005. Since 2006 she is the President of the Turkish Society of Immunology. Most of her work is focused on functional and phenotypical characterization of NK cells, primary immunodeficiencies, allergy and immunohematology.
Betty Diamond received her MD from Harvard Medical School and performed a residency in Internal Medicine at Columbia Presbyterian Medical Center. She received her rheumatology training at the Albert Einstein College of Medicine. She has been Chief of Rheumatology at Albert Einstein and Columbia University and is currently Head of the Center of Autoimmune and Musculoskeletal Diseases at the Feinstein Institute for Medical Research.
Her research has focused on the induction and pathogenicity of autoantibodies in SLE. Most recently, she has become interested in the anti-inflammatory effects of C1q. In recent years, she has also become involved in clinical trials in SLE and has led several clinical trials of novel therapeutics.
She has served on several committees of the American College of Rheumatology (ACR) and has served on the Board of Directors as well. She has received the Outstanding Investigator and the Mentoring award of ACR. She is a member of the National Academy of Medicine and past president of the American Association of Immunologists.
Dr. Kohtaro Fujihashi, D.D.S., Ph.D. is a Professor, Departments Pediatric Dentistry and Microbiology, The University of Alabama at Birmingham. He has been studying T cell immunoregulatory mechanisms in the induction of secretory IgA (SIgA) immunity and oral tolerance for over two decades. During the past five years, his laboratory has extensively assessed mucosal immunity in aging. This work holds promise since nasal vaccine delivery with novel innate immune stimulants, can elicit significant immunity in the upper respiratory tract even in aging. He has published more than 200 scientific publications.
Professor William Heath obtained a Ph.D. in Immunology from the University of Melbourne, Australia. Currently, he is a Professor and an NHMRC Senior Principal Research Fellow at the Department of Microbiology and Immunology, within the Peter Doherty Institute of Infection and Immunity at the University of Melbourne. He has published over 220 papers, with a total of more than 20,000 citations and was made a Fellow of the Australian Academy of Science in 2008.
Noah Isakov is a Professor of Immunology in the Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, at Ben Gurion University of the Negev, in Beer Sheva, Israel, where he holds the Joseph H Krupp Chair in Cancer Immunobiology. He obtained his PhD from the Weizmann Institute of Science in Rehovot, Israel (1981) and worked as a postdoctoral researcher at the University of Minnesota in Minneapolis, MN (1981-1983) and the Scripps Research Institute in La Jolla, CA (1983-1987). He performed sabbaticals at the NICHD, National Institutes of Health in Bethesda, MD (1993-1995), the Oklahoma Medical Research Foundation in Oklahoma City, OK (2003-2004), where he held the Esther Greenberg Honors Chair in Biomedical Research, and the Otago University in Dunedin, New Zealand (2015).
Pascale Kropf did her PhD at Imperial College London on T helper cell responses in experimental leishmaniasis. She is a senior lecturer in Immunology at Imperial College London. The main focus of her work is dissecting the immunological mechanisms responsible for nonhealing human cutaneous and visceral leishmaniasis in Ethiopia.
Cornelis (Kees) JM Melief is emeritus professor at Leiden University and Chief Scientific Officer (CSO) of ISA Pharmaceuticals. He has made many contributions to basic immunology and experimental and clinical tumor immunology. Recently effective immunotherapy of tumors with synthetic long peptides (SLP) was developed in mouse and rabbit models. This has led to the implementation of clinical trials in patients with cancer of viral and non-viral origin. Recently clinical effectiveness was shown in the treatment of patients with established lesions caused by high risk human papilloma virus type 16 (HPV 16).
Seppo Meri, MD, PhD is a Professor of Immunology at the Medical Faculty, University of Helsinki, and Chief Physician of Research in Microbiology at HUSLAB, laboratory of the Helsinki University Hospital, Finland. He served as a postdoctoral fellow at the University of Texas in 1988 and in 1989-90 as an EMBO fellow at MRC, Cambridge, UK. He has published 240 original papers and 130 reviews or textbook chapters on complement, autoimmunity and microbial escape. His research interests include diseases related to disturbances in complement regulation (like hemolytic uremic syndrome), vascular damage and reasons for increased susceptibility to infections.
Heidrun Moll performed her doctoral studies at the Max Planck Institute of Immunobiology, Freiburg, and her post-doctoral training was at WEHI in Melbourne. She was assistant professor at the University of Erlangen Medical School and moved to the then newly established Research Center for Infectious Diseases, Würzburg. Since 1995, she is professor at the University of Würzburg Medical School, and head of the Infection Immunology Unit. Furthermore, she is member of the Scientific Advisory Council of the Robert Koch Foundation. Her scientific achievements were honored with the Siebold Nagasaki Medical Award, and in 2016, with the Rudolf-Leuckart Award.
Dr. Ohashi received her Ph.D from the University of Toronto with Dr. Tak Mak, and did her post-doctoral training at the University of Zurich with the Nobel Laureate Dr. Zinkernagel, and Dr. Hans Hengartner. She is the co-Director of the Campbell Family Institute for Breast Cancer Research, Senior Scientist at the Princess Margaret Cancer Centre, and Professor in the Departments of Medical Biophysics and Immunology at the University of Toronto. She is also the Director of the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre. Her interests are understanding T cell tolerance, strategies to promote tissue specific immune responses and translating these findings to clinical trials.
Andras Perl received his MD and PhD from Semmelweis University in Budapest, Hungary. He was trained in Internal Medicine at Semmelweis and Rheumatology/Immunology at the University of Rochester. He held faculty positions at Semmelweis, the University of Rochester, Roswell Park Memorial Institute, and the State University of New York (SUNY). He has been Professor of Medicine, Microbiology and Immunology since 1997, Chief of Rheumatology since 2001 at SUNY. His team has identified disease susceptibility genes that regulate mitochondrial homeostasis and cell death signal processing in mouse models and patients with autoimmunity, cancer, metabolic diseases, which led to successful clinical trials.
Dr. R. P. Phipps earned his B.S.M.T. in medical technology and graduated magna cum laude at Loyola College, Baltimore, Maryland. Upon completion of his doctorate degree in Microbiology/Immunology, from the Medical College of Virginia, he held postdoctoral fellowships at the Medical College of Virginia and Duke University. In 1983 Dr. Phipps joined the faculty at the University of Rochester.
Dr. Phipps has been awarded six patents; 4 on bacterial auto inducer molecules, 1 on platelet production and 1 on methods to treat thyroid eye disease. Dr. Phipps has received numerous awards and honors including the Arthur Kornberg Research Award, Burroughs-Wellcome Foundation Faculty Scholar, and the University of Rochester Pre and Postdoctoral Student Mentoring Award. Dr. Phipps has dedicated his career to advancing biomedical research.
Dr. Rasley obtained a doctorate (Ph.D.) in Immunology from the University of North Carolina at Charlotte where she studied innate immune responses in the central nervous system. She is currently a Senior Staff Scientist at Lawrence Livermore National Laboratory (LLNL) where much of her research has focused on host-pathogen interactions and nanoparticle mediated immune modulation strategies for infectious diseases. Dr. Rasley is also part of the management team at LLNL overseeing work with pathogens that require advanced biosafety containment.
Dr. Rinaldo is Chairman and Professor of Infectious Diseases and Microbiology (IDM) in the University of Pittsburgh Graduate School of Public Health, Professor of Pathology in the University of Pittsburgh School of Medicine, and Assistant Director of Clinical Microbiology in the University of Pittsburgh Medical Center. He has been the Principal Investigator for the Multicenter AIDS Cohort Study clinical site in Pittsburgh since 1983, which investigates the natural history of HIV-1 infection in men who have sex with men. He also leads an Immunology Specialty Laboratory in the AIDS Clinical Trials Group. He has more than 360 scientific publications. He has served nationally on NIH committees and editorial boards, and was honored with a MERIT award from the NIH for support of his HIV research in 2004.
Alexander Rudensky is Chairman of the Immunology Program and Director of the Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center (MSKCC), an Investigator with the Howard Hughes Medical Institute, and a Tri‐Institutional Professor at MSKCC, the Rockefeller University and Cornell University, and Professor at Gerstner School of Graduate Studies and at Weill‐Cornell Medical School. Dr. Rudensky is an internationally-recognized leader in the field of immune regulation, where he has made numerous seminal discoveries including the identification of the molecular mechanisms of regulatory T cell differentiation. Dr. Rudensky was elected to the National Academy of Sciences in 2012, the American Academy of Sciences and the National Academy of Medicine in 2015. He is the recipient of the Searle Scholar Award and more recently the Coley Award for Basic Science
Dr. Shevach received his A.B. and M.D. degrees from Boston University. He is presently Chief, Cellular Immunology Section, Laboratory of Immunology. Dr. Shevach is the author of over 440 papers in the field of Immunology and his research interests over the years have included antigen presentation and processing, T lymphocyte activation, pathogenesis of autoimmunity, and most recently the role of regulatory T cells in immune responses. He served as Editor-in-Chief of the Journal of Immunology from 1987 to 1992 and as Editor-in-Chief of Cellular Immunology from 1996 to 2007. He is a member of the editorial boards of several journals including Immunity, Journal of Experimental Medicine, and Human Immunology.
Research interests: Our laboratory’s research interests lie in antigen presentation by MHC molecules, and immune response to cancer. Our laboratory has developed innovative approaches for therapy of cancer, infections and autoimmune disorders. It is our view that the HSP-peptide interaction is an evolutionary precursor to the MHC-peptide interaction and lies at the center of a wide array of immunological phenomena. More recently, we have been involved in genomic analysis of tumors as a tool to define the “immunomes” of mouse and human cancers.
Clinical interests: Personalized, individual-specific genomics-driven Immunotherapy of epithelial ovarian cancers.
Shao-Cong Sun received his Ph.D. degree in Microbiology from Stockholm University and pursued postdoctoral training at The Gladstone Institute of Virology and Immunology, University of California at San Francisco. He is a professor and endowed chair in Immunology at The University of Texas MD Anderson Cancer Center, where he also serves as the director of Center for Inflammation and Cancer. His major contributions include demonstration of IkBa degradation in NF-kB activation, discovery of noncanonical NF-kB pathway, and seminal findings of in vivo functions of ubiquitination in regulating T-cell activation and tolerance. He has published more than 150 scientific papers.
Luc Van Kaer received B.S., M.S., and Ph.D. degrees from Ghent University (Ghent, Belgium) and performed postdoctoral research at the Massachusetts Institute of Technology (Cambridge, MA). He subsequently joined the faculty of Vanderbilt University Medical Center (Nashville, TN), where he is currently Professor of Pathology, Microbiology and Immunology. His research program focuses on the immunological functions of innate and innate-like lymphocytes. He previously served as a Section Editor and Deputy Editor with the Journal of Immunology and he currently serves as a Consulting Editor with the Journal of Clinical Investigation. He has been on the Editorial Board of Current Immunology Reviews since 2004.
Dr. Theresa Whiteside is a Professor of Pathology, Otolaryngology and Immunology at the University of Pittsburgh and member of the University of Pittsburgh Cancer Institute. She is a recognized expert in immune monitoring of patients with cancer and has authored over 575 peer-reviewed publications and 127 chapters as well as a book on human tumor-infiltrating lymphocytes, also co-editing several scientific books. She has trained 94 post-doctoral fellows from the United States and abroad.
Her research interests include tumor immunology and immunotherapy. Currently, she is investigating the role of regulatory T cells in cancer progression as well as contributions of tumor-derived exosomes (TEX) to dysfunction of CD8+ effector cells in the peripheral circulation of patients with cancer and in the tumor microenvironment.
Dr. Wu obtained M.D. in Clinical Medicine from the Secondary Military Medical University, Shanghai, and Ph.D. in Immunology from the Third Military Medical University, Chongqing, China. Currently, He is the Director of Institute of Immunology, PLA, China. He has published more than 200 SCI papers and is a named inventor of 90 issued patents.
Dr. Mingjun Wang，Executive President of Shenzhen Institute for Innovation and Translational Medicine, received his MD from Anhui Medical University in China and his PhD degree in Cellular Immunology from the University of Copenhagen in Denmark in 2009, and finished his postdoctoral training in cancer immunology at Baylor College of Medicine in Houston of the United States. Dr. Mingjun Wang has published more than 30 peer-reviewed papers and three book chapters in the field of cancer immunology.
Dr. Md. Asiful Islam completed his PhD in genetics of antiphospholipid syndrome from Human Genome Centre, Universiti Sains Malaysia in 2018. Currently, he is working as a senior lecturer in the same university under the Department of Haematology. He has published 34 (Web of Science-indexed) journal articles so far (total impact factor 2018: 107.057 citations: 554; h-index:13; i10-index: 16). He has been working as an academic editor for the journal PLOS ONE. His current major research interest includes haematological malignancies in autoimmune diseases.